Jagsonpal Pharmaceuticals Limited
All news and filings related to Jagsonpal Pharmaceuticals Limited.
View all news & filings- Medium impact
Jagsonpal Pharma Completes Acquisition of Group Pharma's Wellness Portfolio
Jagsonpal Pharmaceuticals Limited has completed the acquisition of Group Pharmaceuticals Limited's wellness portfolio for an upfront consideration of ~₹23.7 Crore, with an additional ~₹23.0 Crore contingent on FY28 sales. This strategic move aims to bolster JPL's revenue towards its ₹500 Crore target by adding complementary brands and expanding its market reach.
Read the summary - Low impact
Jagsonpal Pharma: Notice on Share Transfer to IEPF & Loss of Share Certificate
Jagsonpal Pharmaceuticals is transferring unclaimed shares to the IEPF by December 28, 2026. A share certificate (No. 231) has been reported lost, with a warning against dealing in it. The company has published these notices in Business Standard (English and Hindi) on September 30, 2026.
Read the summary - Low impact
Jagsonpal Pharmaceuticals Allots 1,01,825 Equity Shares Under ESOP
Jagsonpal Pharmaceuticals allotted 1,01,825 equity shares under its ESOP 2022 plan on September 30, 2026. This increased the paid-up share capital to ₹13,21,18,490, comprising 6,60,59,245 equity shares. Shares were issued upon exercise of vested options.
Read the summary - Low impact
Jagsonpal Pharmaceuticals: Trading Window Closed Oct 1 for Q2 FY27 Results
Jagsonpal Pharmaceuticals will close its trading window from October 1, 2026, for its designated persons and their relatives. This is in anticipation of the declaration of unaudited financial results for the quarter and six months ended September 30, 2026. The window will reopen 48 hours post-announcement.
Read the summary - Medium impact
Jagsonpal Pharma to acquire Group Pharma's Wellness Portfolio for up to ₹46.7 Cr
Jagsonpal Pharmaceuticals will acquire Group Pharmaceuticals' Wellness Portfolio for an initial ₹23.7 crore, with potential additional consideration up to ₹23.0 crore, capping the total at ₹46.7 crore. The transaction is expected to close by November 1, 2026, aiming to strengthen Jagsonpal's presence in women's health and other therapeutic segments.
Read the summary - Medium impact
Jagsonpal Pharma to acquire Group Pharma's Wellness Portfolio for up to ₹46.7 Cr
Jagsonpal Pharmaceuticals will acquire Group Pharmaceuticals' Wellness Portfolio for an initial ₹23.7 Cr, with potential additional consideration up to ₹23 Cr, capping the total at ₹46.7 Cr. The deal is expected to close by November 1, 2026, strengthening Jagsonpal's presence in women's health.
Read the summary - Low impact
Jagsonpal Pharma's 47th AGM: Key Resolutions Passed Unanimously
Jagsonpal Pharmaceuticals Limited held its 47th AGM on September 18, 2026. All five resolutions, including financial statement adoption, dividend declaration, director reappointment, cost auditor remuneration ratification, and independent director appointment, were passed with strong majority. The results were confirmed by the Scrutinizer's Report.
Read the summary - Low impact
Jagsonpal Pharma holds 47th AGM on Sep 18, 2026; declares dividend.
Jagsonpal Pharmaceuticals Limited conducted its 47th AGM on September 18, 2026. Key resolutions included adopting FY26 financial statements, declaring a dividend, and appointing Mr. Anil Kumar Matai as an Independent Director. Voting results are expected within two business days.
Read the summary - Low impact
Jagsonpal Pharma to hold 47th AGM on Sep 21, 2026, via video conference
Jagsonpal Pharmaceuticals will hold its 47th AGM on September 21, 2026, via video conference. The Register of Members will close from September 14 to September 21, 2026. The cut-off date for voting eligibility is September 14, 2026. Remote e-voting will be open from September 18 to September 20, 2026.
Read the summary - Medium impact
Jagsonpal Pharma to hold 47th AGM on Sep 18, 2026; Record date for Dividend: Sep 04, 2026
Jagsonpal Pharmaceuticals Limited will hold its 47th AGM on September 18, 2026. The record date for dividend is September 04, 2026. The company reported FY26 revenue of ₹287 crore and a 19% growth in Operating PAT to ₹43 crore. It completed a ₹40 crore share buyback and recommended a 200% dividend.
Read the summary - Low impact
Jagsonpal Pharmaceuticals Announces 47th AGM on Sep 18, 2026, via VC/OAVM
Jagsonpal Pharmaceuticals Limited will hold its 47th AGM on September 18, 2026, via Video Conferencing. The Annual Report for FY 2025-26, including the AGM notice, is available online for shareholders.
Read the summary - Low impact
Jagsonpal Pharma Allots 27,950 Equity Shares Under ESOP 2022
Jagsonpal Pharmaceuticals Limited allotted 27,950 equity shares under its ESOP 2022 on August 24, 2026. This increases the paid-up share capital to Rs. 13,19,14,840. The shares rank pari passu with existing equity.
Read the summary - Low impact
Jagsonpal Pharmaceuticals Announces 47th AGM on September 18, 2026
Jagsonpal Pharmaceuticals will hold its 47th AGM on September 18, 2026, via Video Conference. A final dividend of ₹4 per share is recommended, with a record date of September 4, 2026. The dividend will be paid within 30 days of AGM approval.
Read the summary - Medium impact
Jagsonpal Pharma Q1 FY27 Earnings Call Transcript Released
Jagsonpal Pharmaceuticals reported Q1 FY27 results with 9% sales growth, 21% EBITDA growth, and 22% PAT growth. The company acquired Aequitas Healthcare for ₹25 crores, providing entry into the hospital segment. A ₹40 crores share buyback was completed. Management targets 1.5x industry growth.
Read the summary - High impact
Jagsonpal Pharmaceuticals Q1 FY27 Earnings Call Transcript Released
Jagsonpal Pharmaceuticals released its Q1 FY27 earnings call transcript. The company reported a 9% revenue growth, with operating EBITDA up 21% and net profits by 22%. A key event was the ₹25 crore acquisition of Aequitas Healthcare. Jagsonpal also completed a ₹40 crore share buyback. The management anticipates Aequitas contributing meaningfully from the second year post-acquisition.
Read the summary - Low impact
Jagsonpal Pharmaceuticals Q1 FY27 Earnings Conference Call Audio Recording Available
Jagsonpal Pharmaceuticals Limited has released the audio recording of its Q1 FY27 Earnings Conference Call held on July 30, 2026. The recording is available on the company's investor relations website for review of the Q1 FY27 financial results.
Read the summary - Low impact
Jagsonpal Pharmaceuticals Publishes Q1 FY27 Unaudited Financial Results
Jagsonpal Pharmaceuticals Limited reported its unaudited financial results for Q1 FY27. Total income from operations was ₹3,76,002 Lakhs, with a net profit after tax of ₹42,418 Lakhs. The EPS stood at ₹3.85 (not annualized). The results were approved by the Board on July 29, 2026.
Read the summary - Low impact
Jagsonpal Pharma Appoints Balmukund Keshav & Sanjay Singhal to Senior Management
Jagsonpal Pharmaceuticals Limited designated Balmukund Keshav as DGM (IT) and Sanjay Singhal as General Manager (CQA & Regulatory Affairs) to its senior management, effective July 29, 2026. Both individuals bring extensive experience in their respective fields.
Read the summary - Low impact
Jagsonpal Pharmaceuticals Grants 1.2 Lakh ESOPs at ₹179.25
Jagsonpal Pharmaceuticals Limited has approved the grant of 1,20,000 employee stock options at an exercise price of ₹179.25 per option. These options will vest in four equal annual tranches starting from the first anniversary of the grant.
Read the summary - High impact
Jagsonpal Pharma Q1 FY27: Revenue Up 9%, PAT Up 22%, Cash Reserves at ₹1,700 Mn
Jagsonpal Pharmaceuticals Limited reported Q1 FY27 results with revenue up 9% YoY to ₹822 Mn and PAT up 22% YoY to ₹132 Mn. Operating EBITDA increased 21% to ₹191 Mn. Cash reserves stood at ₹1,700 Mn. The company completed an 85% stake acquisition in Aequitas Healthcare.
Read the summary - High impact
Jagsonpal Pharma Q1 FY27: Revenue up 9% to ₹82.2 Cr, PAT up 22% to ₹13.2 Cr
Jagsonpal Pharmaceuticals reported Q1 FY27 results with revenue up 9% YoY to ₹82.2 Cr and PAT up 22% YoY to ₹13.2 Cr. Operating EBITDA increased 21% to ₹19.1 Cr. The company completed an 85% acquisition of Aequitas Healthcare for ₹20.8 Cr, marking entry into the hospital business. Cash reserves remain strong at ₹170 Cr.
Read the summary - Medium impact
Jagsonpal Pharmaceuticals Ltd.: AGM on Sep 18, 2026; Record Date Sep 04 for Dividend
Jagsonpal Pharmaceuticals will hold its 47th AGM on September 18, 2026, via VC/OAVM. The company fixed September 04, 2026, as the record date for a recommended dividend of ₹4 per share (200%) for FY26, subject to shareholder approval.
Read the summary - Medium impact
Jagsonpal Pharma Q1FY27 Unaudited Results: Revenue at ₹82.23 Cr, Profit ₹17.68 Cr
Jagsonpal Pharmaceuticals reported unaudited standalone results for Q1FY27. Revenue was ₹82.23 crore and profit ₹13.19 crore. The company acquired an 85% stake in Aequitas Healthcare for ₹20.8 crore and completed a ₹40 crore buyback. A dividend of ₹4 per share was recommended.
Read the summary - Low impact
Jagsonpal Pharmaceuticals Schedules Q1 FY27 Earnings Conference Call for July 30
Jagsonpal Pharmaceuticals Limited will host an investor conference call on Thursday, July 30, 2026, at 2:30 PM IST to discuss its Q1 FY27 financial results. Pre-registration is encouraged for participants.
Read the summary - Medium impact
Jagsonpal Pharmaceuticals Completes Acquisition of 85% Stake in Aequitas Healthcare
Jagsonpal Pharmaceuticals Limited has completed the acquisition of an 85% equity stake in Aequitas Healthcare Private Limited. This follows prior disclosures made on June 29, July 7, and July 8, 2026. The company has officially finalized the transaction.
Read the summary - Low impact
Jagsonpal Pharma Allots 94,000 Equity Shares Under ESOP 2022
Jagsonpal Pharmaceuticals Limited allotted 94,000 equity shares under its ESOP 2022 plan. This increases the paid-up share capital to Rs. 13,18,58,940, comprising 6,59,29,470 equity shares. The allotment took place on July 15, 2026.
Read the summary - Medium impact
Jagsonpal Pharma completes 69.77% stake acquisition in Aequitas, making it a subsidiary.
Jagsonpal Pharmaceuticals Limited has acquired a 69.77% stake in Aequitas Healthcare Private Limited, making Aequitas its subsidiary. This is part of a larger proposed acquisition of 85% stake.
Read the summary - Low impact
Jagsonpal Pharma files SEBI compliance certificate for Q1 FY27
Jagsonpal Pharmaceuticals Limited submitted a compliance certificate for the quarter ended June 30, 2026, as per SEBI regulations. The company confirmed proper processing of dematerialized securities.
Read the summary - Low impact
Jagsonpal Pharma Promoters Declare No Share Encumbrance as of March 31, 2026
Promoters and persons acting in concert of Jagsonpal Pharmaceuticals Limited, including Infinity Holdings and Rajpal Singh Kochhar, have declared no encumbrance on their shares as of March 31, 2026. Disclosures were made to BSE and NSE on April 6-9, 2026.
Read the summary - Medium impact
Jagsonpal Pharma to acquire 85% stake in Aequitas for ₹20.8 Cr, entering hospital segment
Jagsonpal Pharmaceuticals will acquire an 85% stake in Aequitas Healthcare for ₹20.8 crore. Aequitas, with FY26 revenues of ₹53 crore, focuses on hospital sales. The deal, funded internally, aims to establish Jagsonpal's presence in the growing hospital segment and is expected to conclude by July 15, 2026.
Read the summary - Medium impact
Jagsonpal Pharma to acquire 85% stake in Aequitas Healthcare for ₹20.8 Cr
Jagsonpal Pharmaceuticals will acquire an 85% stake in Aequitas Healthcare for ₹20.8 crore in cash. The deal is expected to close by July 15, 2026. Aequitas reported ₹53.31 crore revenue in FY26 and focuses on hospital sales. This acquisition aims to strengthen Jagsonpal's presence in the hospital segment.
Read the summary - Low impact
Jagsonpal Pharma Allots 2.96 Lakh Equity Shares Under ESOP 2022
Jagsonpal Pharmaceuticals Limited allotted 2,96,320 equity shares under its ESOP 2022 plan on June 4, 2026. This increased the paid-up share capital to Rs. 13,16,70,940 from Rs. 13,10,78,300.
Read the summary - Low impact
Jagsonpal Pharma: Promoters Report No Share Encumbrance for FY26
Infinity Holdings and associated parties declare no share encumbrance for Jagsonpal Pharmaceuticals Limited during FY26. This disclosure is made as per SEBI Takeover Regulations, ensuring promoter transparency. The announcement was broadcast on April 6, 2026.
Read the summary - Low impact
Jagsonpal Pharma extinguishes 16 lakh shares post buyback completion
Jagsonpal Pharmaceuticals Limited has extinguished 16,00,000 equity shares post its buyback program. The company's share capital reduced from 6,71,39,150 to 6,55,39,150 equity shares. The buyback tender period was from May 8 to May 14, 2026.
Read the summary - Low impact
Jagsonpal Pharmaceuticals: Pallavi Dinodia Gupta Resigns as Independent Director
Pallavi Dinodia Gupta resigned as Independent Director of Jagsonpal Pharmaceuticals, effective May 18, 2026, due to personal reasons. Consequently, she will cease to be a member of the Audit Committee, Corporate Social Responsibility Committee, and Chairperson of the Stakeholders Relationship Committee. She also holds directorships in IndiaMART InterMESH, Voith Paper Fabrics India, and Lumax Industries.
Read the summary - Low impact
Jagsonpal Pharma: Buyback Offer Opening Advertisement Published in Newspapers
Jagsonpal Pharmaceuticals Limited has published its buyback offer opening advertisement. The buyback opens on May 08, 2026, and closes on May 14, 2026. The Letter of Offer was dispatched on May 06, 2026, to shareholders on record as of May 04, 2026.
Read the summary - Medium impact
Jagsonpal Pharma to Buy Back 16 Lakh Shares Worth ₹40 Crore at ₹250 Each
Jagsonpal Pharmaceuticals Limited will buy back 16 lakh equity shares at ₹250 each, totaling ₹40 crore. The buyback opens on May 8, 2026, and closes on May 14, 2026. The record date is May 4, 2026.
Read the summary - Medium impact
Jagsonpal Pharma announces ₹40 Cr buyback offer at ₹250 per share
Jagsonpal Pharmaceuticals Limited is launching a buyback of up to 16 lakh equity shares at ₹250 per share, totaling ₹40 crore. The buyback period runs from May 8 to May 14, 2026. This offer represents 2.38% of the company's total equity share capital.
Read the summary - Medium impact
Jagsonpal Pharma Approves Buyback of 16 Lakh Shares Worth ₹40 Crore
Jagsonpal Pharmaceuticals Limited will buy back up to 16,00,000 equity shares at ₹250 per share, totaling ₹40 crore. The record date is May 4, 2026. Promoters will not participate. The buyback aims to return surplus cash to shareholders and is expected to improve ROCE by 400 bps.
Read the summary - Low impact
Jagsonpal Pharmaceuticals publishes audited financial results for FY26
Jagsonpal Pharmaceuticals Limited published its audited financial results for the quarter and financial year ended March 31, 2026. The results were advertised in Business Standard (English and Hindi) on April 29, 2026, as per SEBI regulations.
Read the summary - Low impact
Jagsonpal Pharma Q4 FY26 Earnings Conference Call Audio Recording Available
Jagsonpal Pharmaceuticals Limited has released the audio recording of its Q4 FY26 Earnings Conference Call. The call took place on April 28, 2026, to discuss financial results. The recording is available on the company's website.
Read the summary - Medium impact
Jagsonpal Pharma sets May 4, 2026 as Record Date for ₹40 Cr Share Buyback
Jagsonpal Pharmaceuticals Limited has fixed May 04, 2026, as the Record Date for its share buyback program. The company plans to buy back up to 16,00,000 equity shares at ₹250 per share, totaling ₹40 crores.
Read the summary - Low impact
Jagsonpal Pharmaceuticals Grants 1,93,000 Employee Stock Options
Jagsonpal Pharmaceuticals Limited has approved the grant of 1,93,000 employee stock options under its ESOP Plan, 2022. The exercise price is ₹159.50 per option. Vesting will occur in four equal annual tranches starting one year from the grant date.
Read the summary - Medium impact
Jagsonpal Pharmaceuticals recommends ₹4 dividend for FY26
Jagsonpal Pharmaceuticals recommended a dividend of ₹4 per equity share for the financial year ended March 31, 2026. The dividend requires shareholder approval at the 47th AGM. Record and payment dates are to be announced.
Read the summary - High impact
Jagsonpal Pharma Q4 FY26: Revenue up 10%, PAT up 31%; ₹40 Cr Buyback Approved, 200% Dividend Proposed
Jagsonpal Pharmaceuticals reported Q4 FY26 revenue up 10% to ₹64.2 crore and PAT up 31% to ₹8.8 crore. For FY26, revenue grew 7% to ₹287.2 crore, and PAT rose 19% to ₹44.6 crore. The company proposed a 200% dividend and approved a ₹40 crore share buyback at ₹250 per share.
Read the summary - High impact
Jagsonpal Pharma Q4FY26: Revenue Up 10% to ₹64.2 Cr, PAT Up 31% to ₹8.8 Cr; ₹40 Cr Buyback Approved
Jagsonpal Pharmaceuticals reported Q4 FY26 revenue of ₹64.2 Cr, up 10%, and PAT of ₹8.8 Cr, up 31%. FY26 revenue was ₹287.2 Cr, with PAT at ₹44.6 Cr, up 19%. The company proposed a 200% dividend and approved a ₹40 Cr buyback at ₹250 per share. Cash position stands at ₹190.7 Cr.
Read the summary - Medium impact
Jagsonpal Pharma Recommends ₹4 Dividend; Q4 FY26 Standalone Results Declared
Jagsonpal Pharmaceuticals recommended a ₹4 per share dividend for FY26. The company declared its audited standalone financial results for the quarter and year ended March 31, 2026. A buy-back of up to 1,600,000 shares at ₹250 each, not exceeding ₹400 million, was also approved.
Read the summary - Medium impact
Jagsonpal Pharmaceuticals recommends ₹4 dividend; Q4 FY26 standalone results approved.
Jagsonpal Pharmaceuticals' Board approved audited standalone financial results for Q4 FY26. The company recommended a final dividend of ₹4 per share. For FY26, total income was ₹2,769.06 million and profit before tax was ₹575.18 million. A buy-back of up to ₹400 million was also approved.
Read the summary - Medium impact
Jagsonpal Pharma Shareholders Approve ₹40 Crore Equity Share Buyback
Jagsonpal Pharmaceuticals shareholders approved a buyback of up to 16 lakh equity shares at ₹250 per share, aggregating to ₹40 Crores. This move aims to enhance shareholder value, optimize capital allocation, and improve EPS.
Read the summary - Medium impact
Jagsonpal Pharma's Buyback Approved: 1.6 Million Shares at ₹250 Each
Jagsonpal Pharmaceuticals Limited's shareholders approved a buy-back of up to 1.6 million equity shares at ₹250 per share, totaling ₹40 crores. The resolution passed with 99.994% of votes in favor during postal ballot and remote e-voting, which concluded on April 24, 2026.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio - Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio - Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio - Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio